Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

Wicki, Andreas; Witzigmann, Dominik; Balasubramanian, Vimalkumar; Huwyler, Jörg

doi:10.1016/j.jconrel.2014.12.030

Cited by 1,615 publications

(1,139 citation statements)

References 237 publications

Supporting

Mentioning

1,115

Contrasting

Unclassified

Order By: Relevance

“…[24] In terms of nanomedicine, it is crucial to develop effective techniques that will improve the specificity in delivering the drug-loaded nanoparticles to the diseased tissue and cells, so that the healthy cells remain unaffected from the therapeutic agents. [74] Cancer cells overexpress certain receptors relative to the normal cells due to the difference in protein expression. One effective strategy to achieve drug targeting is to incorporate the ligands over the nanoparticle surface that can target the overexpressed receptors on the cancer cells resulting in higher internalization.…”

Section: Antibody-conjugated Nanoparticle Using Physical Adsorptionmentioning

confidence: 99%

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates

Sivaram

Wardiana

Howard

et al. 2017

Adv Healthcare Materials

100

View full text Add to dashboard Cite

Targeted nanomedicines have significantly changed the way new therapeutics are designed to treat disease. Central to successful therapeutics is the ability to control the dynamics of protein–nanomaterial interactions to enhance the therapeutic effect of the nanomedicine. The aim of this review is to illustrate the diversity and versatility of the conjugation approaches involved in the synthesis of antibody–nanoparticle conjugates, and highlight significant new advances in the field of bioconjugation. Such nanomedicines have found utility as both advanced therapeutic agents, as well as more complex imaging contrast agents that can provide both anatomical and functional information of diseased tissue. While such conjugates show significant promise as next generation targeted nanomedicines, it is recognized that there are in fact no clinically approved targeted therapeutics on the market. This fact is reflected upon within this review, and attempts are made to draw some reasoning from the complexities associated with the bioconjugation chemistry approaches that are typically utilized. Present trends, as well as future directions of next generation targeted nanomedicines are also discussed.

show abstract

Section: Antibody-conjugated Nanoparticle Using Physical Adsorptionmentioning

confidence: 99%

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates

Sivaram

Wardiana

Howard

et al. 2017

Adv Healthcare Materials

100

View full text Add to dashboard Cite

show abstract

“…There are over 1000 clinical trials containing the terms "liposome" and "cancer," either completed or active, according to The National Institutes of Health's (NIH) web-based database, ClinicalTrials.gov and the EU Clinical Trial Register. There are several ongoing clinical trials investigating the efficiency of liposomal cisplatin, NDDP (cisplatin analog), paclitaxel, mitoxantrone, irinotecan, SN38 (the active metabolite of irinotecan), topotecan, lurtotecan, a camptothecin analog, vinorelbine, annamycin, docetaxel, DOX, and vincristine [83][84][85][86][87]. The association of chemotherapeutic drugs is a frequently used strategy in chemotherapy.…”

Section: Clinical Experience With Liposomes For Cancer Chemotherapymentioning

confidence: 99%

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Porfire¹,

Achim²,

Tefas³

et al. 2017

Liposomes

View full text Add to dashboard Cite

The liposomes present great potential for applications in targeted delivery of chemotherapeutics in the treatment of cancer. The use of liposomal drug carriers as vehicles for targeting of chemotherapeutic agents to tumor tissues is based on their advantages over other dosage forms, represented by their low systemic toxicity, their bioavailability, and their possibility to enhance the solubility of different chemotherapeutic agents, due to the ability to encapsulate both hydrophilic and lipophilic drugs. They enhance the therapeutic index of anticancer drugs by increasing the drug concentration in tumor cells through tumor targeting. The available approaches used for tumor targeting using liposomes are passive targeting, active targeting, and triggered drug release. The most advanced targeting strategies proposed for cancer treatment are the development of multifunctional liposomes, having combined targeting mechanism. In this chapter, the tumor-targeting mechanisms are described in detail as well as the possibilities to design the targeted liposomal nanocarrier in order to reach the desired target in the body and minimizing the off-target effects. Moreover, the current status of preclinical and clinical evaluation is highlighted.

show abstract

“…[2][3][4][5][6][7] The application of nanotechnology in cancer therapy, herein referred as cancer nanomedicines, have received wide spread attention due to the unique physicochemical properties of the nanoparticles with the ability to deliver different therapeutics (e.g., chemotherapeutics and biologics), altering their pharmacokinetic profiles, augmenting their accumulation in the tumors and reducing their toxicity profiles. [8][9][10][11] Nanomedicines aim to improve the balance between therapeutic efficacy and systemic toxicity of conventional chemotherapeutic agents, which lack of specificity, thereby enhancing the therapeutic index of the anticancer drugs. In clinical cancer care more evidences have been suggested that nanoparticles found to be localized in solid tumors after the systemic (intravenous) administration of nanomedicines to cancer patients.…”

Section: Introductionmentioning

confidence: 99%

“…In clinical cancer care more evidences have been suggested that nanoparticles found to be localized in solid tumors after the systemic (intravenous) administration of nanomedicines to cancer patients. [9,12,13] In addition, compared to the conventional anticancer drugs, nanomedicine have shown many benefits in terms of improved half-life in blood circulation, enhanced drug bioavailability with reduced side effects of the parental drugs. Anti-cancer nanomedicines are rapidly emerging as a promising approach and offers the possibilities to the clinicians to overcome the limitations of current cancer therapy.…”

Section: Introductionmentioning

confidence: 99%

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Balasubramanian

Liu

Hirvonen

et al. 2017

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.

show abstract

Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

Cited by 1,615 publications

References 237 publications

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates

Liposomal Nanoformulations as Current Tumor-Targeting Approach to Cancer Therapy

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Contact Info

Product

Resources

About